Centiva Capital, LP Maxcyte, Inc. Transaction History
Centiva Capital, LP
- $4.65 Billion
- Q4 2024
A detailed history of Centiva Capital, LP transactions in Maxcyte, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 24,993 shares of MXCT stock, worth $83,476. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,993Holding current value
$83,476% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding MXCT
# of Institutions
123Shares Held
69.8MCall Options Held
8.7KPut Options Held
6K-
Cadian Capital Management, LP New York, NY9.34MShares$31.2 Million2.26% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$27.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.43MShares$18.1 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$16.8 Million18.06% of portfolio
-
Morgan Stanley New York, NY4.41MShares$14.7 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $340M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...